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SUMMARY 
Trichothecenes are mycotoxins which produce Iethai toxicosis in humans and animals, yet no adequate 
therapeutic regimen has been developed. This study provides evidence that the selective platelet activating 
factor (PAF) antagonist, BN 52021 (5-15 mg/kg i.v.) can prolong the survival of conscious rats exposed 
to a highly Iethai T -2 toxicosis. These data also suggest that P AF is an important mediator of this unique 
toxicosis. 
INTRODUCTION 
Trichothecenes are a chemically related group of biologically active fungal 
metabolites. T -2 toxin, a trichothecene mycotoxin, is a natural contaminant of 
foods and animal feeds that may cause severe illness in animals and humans [1] 
through deranged cardiorespiratory functions [2]. Although T -2 toxicosis is a 
disorder that has been associated with epidemic outbreaks in many countries, no 
specific therapy has been established for humans or animals. Recently, murine 
monoclonal antibody against T -2 toxin successfully protected and reversed severe 
T -2 toxicosis in the rat [2]. However, such therapeutic approach cannot be easily 
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extrapolated to humans since no human anti-T -2 antibody is available to date. 
Recently, a potent and selective PAF-acether antagonist, BN 52021, (9Hl,7a-
(epoxymethano)-1H,6aH-cyclopenta[c] furo [2,3-b] furo-[3' ,2' ,3,4) cyclopenta [1 ,2-
d]furan-5,9, 12-(411)-trione, ß-tert-butylhexahydro-4,-7b,-ll hydroxy-8 methyl) was 
shown to provide substantial protection in several models of shock including en-
dotoxemia [3,4}. Since lipopolysaccharide endotoxemia shows hemodynamic, 
cellular and endocrine similarities with T -2 toxicosis [5], we postulated tbat a P AF-
acether antagonist might have a beneficial effect on survival from severe T-2 tox-
icosis. 
METHODS 
Male Sprague-Dawley rats (250-300 g) were chronically implanted with a PE-50 
catheter in the femoral vein as previously described [2). Three different protocols 
were used in which rats were subjected to i. v. injection of 0.65 mg/kg of T -2 toxin 
(Sigma, St. Louis, MO) in 200 ~tl of 1007o ethanol in 0.90Jo saline (sterile, pyrogen-
free). This dose of T-2 toxin was selected from dose-response curves constructed in 
the conscious rat [2). Three different groups of rats were treated as follows: (1) BN 
52021 (kindly provided by Dr. P. Braquet, IHB, France) 15 mg/kg, 3 h after T -2 
administration; (2) BN 52021, 15 mg/kg, 30 min prior to and 8 h after T-2 ad-
ministration; (3) BN 52021, 5 mg/kg, 30 min and 6 h after T-2 administration. BN 
52021 was injected in 150-400 pl of 50'/o DMSO in 0.90'/o NaCI. Control rats received 
the vehicle injections of the T-2 and BN 52021 solvents. The vehicles used were 
shown to have absolutely no untoward effects in the rat. The rats were kept in single 
cages with food and water ad libitum for the complete duration of the experiment. 
Statistics 
Fisher's exact probability test was used to evaluate the difference in survival ratio 
between the control and BN 52021-treated groups. 
RESULTS 
In each group of rats treated with BN 52021, a substantial increase in survival rate 
was clearly demonstrated (Fig. 1 ). Most remarkably, a single dose of BN 52021 
quadrupled the ultimate survival rate of the rats (Fig. 1, middle panel). 
DISCUSSION 
Although P AF -acether has not been demonstrated in T -2 toxicosis as yet, our 
data infer a role for PAF-acether also in the pathophysiology ofT -2 toxicosis. This 
conclusion is based on previous studies showing that BN 52021 is a potent and selec-
tive P AF -acether antagonist [6]. Nevertheless, the substantial protective effect of 
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Fig. 1. Effect of BN 52021 on survival of rats exposed to T-2 toxin. Open circles·represent vehicle-treated 
rats; closed circles represent BN 52021-treated rats. Time of BN 52021 injection is denoted by il. T-2 
toxin was injected always at 0 time. Numbers of rats in each group are given in parentheses for each 
panel. Asterisks denote statistical significance at P < 0.05 for the upper and lower panels and P < 0.02 
for the middle panel. 
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BN 52021 in this highly Iethai mycotoxicosis might prove to be of beneficial effect 
in protecting livestock and hornans exposed to trichothecene mycotoxins. 
Since T -2 toxicosis is associated with widespread metabolic hematologic, 
respiratory and cardiovascular derangements it is difficult to assess at this point the 
exact contribution of P AF in these pathophysiological processes. Further studies 
will be needed to identify PAF in T-2 toxicosis and to identify its primary target 
organs and systems. 
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